Necessary approval by the Government agency called Food and Drugs Administration better known as the FDA is the prime mandatory factor for any branded or generic medicine manufacturers before introducing their drug products into the markets. There are certain parameters and safety factors considered stringently by this agency for safeguarding the general public health. Preset norms and thorough clinical tests and examinations are involved before clearing any products for public use including the efficacy and side effects of the individual product.

TriCor Tablets – the micronized form of the drug called Fenofibrate produced and distributed by Abbot Laboratories and Groupe Fournier, received the formal approval by the Food and Drug Administration-FDA of the United States precisely on the 12th of February, 1998 for treating the patients with very high triglyceride levels. TriCor is the brand set for the medicine for sale within the United States while the drug is sold in 77 other countries across the world under the brands like Lipanthyl and Lipidil.

TriCor is indicated in the United States of America as an addition to the recommended diet chart for treating the adult patients who are having excessively raised serum triglyceride levels, especially Types IV and V hyperlipidemia that are not properly managed merely by the diet plan and are rather at the higher risk to the ailment like pancreatitis. The FDA also states that TriCor – Fenofibrate tablets should not be used for treating the patients having disease related to their liver, gall bladder or any serious kind of kidney ailment or for treating the patients who are allergic to the specific drug.